Cargando…

Monoclonal antibody therapies against SARS-CoV-2

Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs and their effect as therapeutics in the pandemic, including structural classification, outcomes in clinical trials that led t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Focosi, Daniele, McConnell, Scott, Casadevall, Arturo, Cappello, Emiliano, Valdiserra, Giulia, Tuccori, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255948/ https://www.ncbi.nlm.nih.gov/pubmed/35803289 http://dx.doi.org/10.1016/S1473-3099(22)00311-5

Ejemplares similares

Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline
por: Tuccori, Marco, et al.
Publicado: (2020)

Prescription of Anti-Spike Monoclonal Antibodies in COVID-19 Patients with Resistant SARS-CoV-2 Variants in Italy
por: Focosi, Daniele, et al.
Publicado: (2022)

The Omicron variant of concern: Diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies
por: Focosi, Daniele, et al.
Publicado: (2022)

SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern
por: Casadevall, Arturo, et al.
Publicado: (2023)

Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients
por: Convertino, Irma, et al.
Publicado: (2020)

The Impact of the COVID-19 “Infodemic” on Drug-Utilization Behaviors: Implications for Pharmacovigilance
por: Tuccori, Marco, et al.
Publicado: (2020)

SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies
por: Focosi, Daniele, et al.
Publicado: (2021)

Spike mutations in SARS-CoV-2 AY sublineages of the Delta variant of concern: implications for the future of the pandemic
por: Focosi, Daniele, et al.
Publicado: (2022)

Convergent Evolution in SARS-CoV-2 Spike Creates a Variant Soup from Which New COVID-19 Waves Emerge
por: Focosi, Daniele, et al.
Publicado: (2023)

Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysis
por: Focosi, Daniele, et al.
Publicado: (2022)

Analysis of Immune Escape Variants from Antibody-Based Therapeutics against COVID-19: A Systematic Review
por: Focosi, Daniele, et al.
Publicado: (2021)

A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment
por: Focosi, Daniele, et al.
Publicado: (2022)

The Road towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins (Hyperimmune Serum) for Passive Immunization in COVID-19
por: Focosi, Daniele, et al.
Publicado: (2021)

Mucosal Vaccines, Sterilizing Immunity, and the Future of SARS-CoV-2 Virulence
por: Focosi, Daniele, et al.
Publicado: (2022)

Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources
por: Sullivan, David J., et al.
Publicado: (2022)

Nirmatrelvir and COVID-19: development, pharmacokinetics, clinical efficacy, resistance, relapse, and pharmacoeconomics
por: Focosi, Daniele, et al.
Publicado: (2023)

Antibodies and SARS-CoV-2: New Data on Diagnostics and Therapeutics
por: Focosi, Daniele, et al.
Publicado: (2022)

Rise of the BQ.1.1.37 SARS-CoV-2 Sublineage, Italy
por: Focosi, Daniele, et al.
Publicado: (2023)

SARS-CoV-2: Advances in Serological Methods and the Understanding of Antibody Escape
por: Focosi, Daniele, et al.
Publicado: (2023)

On the Need to Determine the Contribution of Anti-Nucleocapsid Antibodies as Potential Contributors to COVID-19 Convalescent Plasma Efficacy
por: Focosi, Daniele, et al.
Publicado: (2022)

Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1
por: Sullivan, David J, et al.
Publicado: (2022)

Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1
por: Sullivan, David J., et al.
Publicado: (2023)

Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2
por: Xie, Jiajia, et al.
Publicado: (2021)

Convalescent plasma in outpatients with COVID-19
por: Focosi, Daniele, et al.
Publicado: (2022)

High-Dose Convalescent Plasma for Treatment of Severe COVID-19
por: Focosi, Daniele, et al.
Publicado: (2022)

Current status of therapeutic monoclonal antibodies against SARS-CoV-2
por: Kumar, Sanjeev, et al.
Publicado: (2021)

In-Silico Analysis of Monoclonal Antibodies against SARS-CoV-2 Omicron
por: Hu, Ye-Fan, et al.
Publicado: (2022)

WHO Is Recommending against the Use of COVID-19 Convalescent Plasma in Immunocompromised Patients?
por: Franchini, Massimo, et al.
Publicado: (2023)

In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains
por: Diamond, Michael, et al.
Publicado: (2021)

Recombination in Coronaviruses, with a Focus on SARS-CoV-2
por: Focosi, Daniele, et al.
Publicado: (2022)

What is the optimal usage of coronavirus disease 2019 convalescent plasma donations?
por: Focosi, Daniele, et al.
Publicado: (2021)

Efficacy of High-Dose Polyclonal Intravenous Immunoglobulin in COVID-19: A Systematic Review
por: Focosi, Daniele, et al.
Publicado: (2022)

Monoclonal antibody-based therapies for microbial diseases
por: Saylor, Carolyn, et al.
Publicado: (2009)

A Web Tool to Estimate Baseline Anti-Spike Monoclonal Antibody Efficacy Based on Regional Genomic Surveillance
por: Focosi, Daniele
Publicado: (2023)

Monoclonal Antibodies and Toxins—A Perspective on Function and Isotype
por: Chow, Siu-Kei, et al.
Publicado: (2012)

SARS-CoV-2 infection, vaccination and acquired hemophilia: Reply
por: Franchini, Massimo, et al.
Publicado: (2023)

Monoclonal Antibodies against SARS-CoV-2: Current Scenario and Future Perspectives
por: Quiros-Roldan, Eugenia, et al.
Publicado: (2021)

Correction: Current status of therapeutic monoclonal antibodies against SARS-CoV-2
por: Kumar, Sanjeev, et al.
Publicado: (2022)

Development of novel monoclonal antibodies against nsp12 of SARS-CoV-2
por: Machitani, Mitsuhiro, et al.
Publicado: (2022)

Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2
por: Yu, Fei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_i19ld8ntjhifo9qg9jtaluifs2